Ascendiant Capital Markets Lowers Alzamend Neuro (NASDAQ:ALZN) Price Target to $35.00

Alzamend Neuro (NASDAQ:ALZN) had its price objective decreased by Ascendiant Capital Markets from $50.00 to $35.00 in a research note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock.

Alzamend Neuro Trading Up 2.0 %

NASDAQ:ALZN opened at $1.53 on Monday. The company’s 50 day moving average price is $1.73 and its 200-day moving average price is $3.51. Alzamend Neuro has a 52 week low of $1.40 and a 52 week high of $19.20.

Alzamend Neuro (NASDAQ:ALZN) last issued its earnings results on Wednesday, September 11th. The company reported ($1.25) EPS for the quarter, beating the consensus estimate of ($2.38) by $1.13. Sell-side analysts expect that Alzamend Neuro will post -14.27 EPS for the current year.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Virtu Financial LLC acquired a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 26,482 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned 0.38% of Alzamend Neuro as of its most recent SEC filing. Institutional investors own 49.61% of the company’s stock.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.